Keymed Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

A clinical-stage biotech developing novel antibody therapeutics for cancer and autoimmune diseases.

OncologyImmunology

Integrated antibody discovery and engineering platform for generating monoclonal, bispecific, and conjugated antibodies.

Potential to license out global rights to advanced candidates or form co-development partnerships with large pharma companies.

High clinical development risk and the substantial capital required to progress multiple assets through late-stage trials.

Competes in the crowded but high-growth field of antibody therapeutics in China, requiring clear differentiation in efficacy or safety to stand out.